Discussing the price of dabrafenib and its use in treatment

Dabrafenib (Tafinlar), a potent and highly selective BRAF kinase inhibitor from GlaxoSmithKline, has become an important force in the field of cancer treatment. Especially for patients with unresectable or metastatic melanoma who are BRAF V600 gene mutation-positive, dabrafenib brings hope for treatment.

Dabrafenib is used alone, mainly for patients with melanoma with BRAF V600E mutation. But even more striking is that when it is combined with trametinib, its treatment scope is expanded to melanoma with BRAF V600E or V600K mutations, as well as metastatic non-small cell lung cancer and anaplastic thyroid cancer with BRAF V600E mutations.

However, it is worth noting that dabrafenib is not suitable for patients with BRAF wild-type melanoma and non-small cell lung cancer. During treatment, patients also need to pay attention to indicators such as their skin condition and heart function to prevent and respond to possible adverse reactions.

Dabrafenib has been widely sold in the domestic market and has been included in medical insurance. Among them, the original version has two specifications, namely 75mg 120 capsules and 50mg 120 capsules. After reimbursement by medical insurance, the price of 75mg medicine is about 12,000 yuan.

In the international market, dabrafenib has also attracted considerable attention. For example, the original drug of Novartis Pharmaceuticals sells for 11,000 yuan per box in the Turkish market, with a specification of 75mg and 120 tablets. At the same time, there are a variety of generic drugs available on the market, with a unified specification of 75 mg and 120 pills, and the price is relatively low, about 2,700 yuan.

Whether it is an original drug or a generic drug, dabrafenib plays a pivotal role in cancer treatment. However, during use, patients still need to strictly follow medical instructions to ensure the safety and effectiveness of the drug.